G. Sumalatha

A new method was established simultaneous estimation of calcipotriene and dipropionate by RP-HPLC method. The chromatographic conditions were successfully developed for the separation of calcipotriene and dipropionate by using coloumn xterr C-18(4.6*250mm) 5µm, flow rate was 1.0ml/min mobile phase ratio Phosphate buffer (0.05M) pH 3.6: ACN (40:60%v/v) (pH was adjusted with ortho phosphoric acid), detection wave length 260nm.the instrument used was water HPLC auto sampler and PDA or detector. The analytical method was validated to ICH guidelines. The linearity range Dipropionate   and Calcipotriene were found to be from 100-500 µg/ml of Dipropionate and 1-5µg/ml of Calcipotriene. Linear regression coefficient was not more than 0.999.

Cancer is currently one of the major diseases that has gained a lot of scientific attention. Conventional cancer therapeutics involve surgical removal of tumors from patients followed by chemotherapeutic treatment. In the use of anticancer drugs during the chemotherapy process, patients often suffer from a variety of undesirable side effects including damage to normal organs. Thus, there is an urgent need for the development of novel strategies to overcome these side effect issues. Malignant diseases are one of the major causes of death in the western world. Patients are treated by surgery, radiation and chemotherapy. Chemotherapeutic treatment is used to decrease the tumour burden and to eliminate malignant cells. However, in most cases, resistance against chemotherapy develops. Therefore, there is a permanent need for new additional treatment strategies and chemotherapeutic combination regimens. In the present review article, the authors try to highlight the most promising approaches and summarize a selection of potential targets and compounds which might become alternative treatment options against malignant diseases.